Paul Baverel

591 total citations
28 papers, 442 citations indexed

About

Paul Baverel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Statistics and Probability. According to data from OpenAlex, Paul Baverel has authored 28 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Statistics and Probability. Recurrent topics in Paul Baverel's work include Cancer Immunotherapy and Biomarkers (10 papers), Peptidase Inhibition and Analysis (4 papers) and Statistical Methods in Clinical Trials (4 papers). Paul Baverel is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Peptidase Inhibition and Analysis (4 papers) and Statistical Methods in Clinical Trials (4 papers). Paul Baverel collaborates with scholars based in United States, Switzerland and United Kingdom. Paul Baverel's co-authors include Lorin Roskos, Rajesh Narwal, Yong Ben, Pralay Mukhopadhyay, Paolo Vicini, Ashok Gupta, Xiaoping Jin, Piet H. van der Graaf, John A. Smith and Ashley Woodcock and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Paul Baverel

27 papers receiving 429 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paul Baverel United States	10	210	133	90	87	67	28	442
Shweta Vadhavkar France	8	116 0.6×	36 0.3×	53 0.6×	24 0.3×	56 0.8×	20	286
Benjamin A. Derman United States	13	297 1.4×	72 0.5×	63 0.7×	52 0.6×	25 0.4×	80	636
Yoshikazu Kamiya Japan	10	385 1.8×	60 0.5×	59 0.7×	74 0.9×	19 0.3×	18	583
Rakesh Chopra India	8	224 1.1×	164 1.2×	33 0.4×	32 0.4×	37 0.6×	14	558
Chin-Yu Lin United States	7	133 0.6×	327 2.5×	16 0.2×	87 1.0×	107 1.6×	8	494
Xiaofei F. Wang United States	14	283 1.3×	254 1.9×	12 0.1×	51 0.6×	49 0.7×	31	638
Run Fan United States	13	265 1.3×	123 0.9×	76 0.8×	22 0.3×	47 0.7×	25	588
Mitchell S. von Itzstein United States	11	222 1.1×	101 0.8×	60 0.7×	15 0.2×	29 0.4×	32	344
Marie Cullberg Sweden	10	141 0.7×	198 1.5×	181 2.0×	162 1.9×	9 0.1×	27	570

Countries citing papers authored by Paul Baverel

Since Specialization

Citations

This map shows the geographic impact of Paul Baverel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Baverel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Baverel more than expected).

Fields of papers citing papers by Paul Baverel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Baverel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Baverel. The network helps show where Paul Baverel may publish in the future.

Co-authorship network of co-authors of Paul Baverel

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Baverel. A scholar is included among the top collaborators of Paul Baverel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Baverel. Paul Baverel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Steeghs, Neeltje, Carlos Gomez‐Roca, Eelke Gort, et al.. (2024). Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2573–2573. 2 indexed citations

Jongen‐Lavrencic, Mojca, Thomas Pabst, Pierre Bories, et al.. (2024). MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study. Blood. 144(Supplement 1). 2881–2881. 4 indexed citations

Stavropoulou, Vaia, Alison Ribeiro, Hilde De Winter, et al.. (2024). 612 Comprehensive biomarker analyses from a phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin. Regular and Young Investigator Award Abstracts. A704–A704. 1 indexed citations

Ruiz-Garcı́a, Ana, Paul Baverel, Dean Bottino, et al.. (2023). A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. Journal of Pharmacokinetics and Pharmacodynamics. 50(3). 147–172. 28 indexed citations

Gomez‐Roca, Carlos, Neeltje Steeghs, Eelke Gort, et al.. (2023). Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 2584–2584. 3 indexed citations

Pabst, Thomas, Mojca Jongen‐Lavrencic, Steffen Boettcher, et al.. (2023). MP0533, a CD3-Engaging Darpin Targeting CD33, CD123, and CD70 in Patients with Relapsed/Refractory AML or MDS/AML: Preliminary Results of a Phase 1/2a Study. Blood. 142(Supplement 1). 2921–2921. 3 indexed citations

Winter, Hilde De, Vaia Stavropoulou, Paul Baverel, et al.. (2022). 1475 A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors. A1534–A1534. 1 indexed citations

Micallef, Sandrine, Alexandre Sostelly, Jiawen Zhu, Paul Baverel, & François Mercier. (2022). Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial. Contemporary Clinical Trials Communications. 26. 100901–100901. 7 indexed citations

Baverel, Paul, et al.. (2021). Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models. CPT Pharmacometrics & Systems Pharmacology. 11(2). 133–148. 6 indexed citations

10.

González, Ignacio Ferreira, et al.. (2021). Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total. Pharmaceutics. 13(4). 519–519. 4 indexed citations

11.

Guo, Xiang, Paul Baverel, Ignacio Ferreira González, et al.. (2021). Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma. OncoImmunology. 10(1). 1898104–1898104. 10 indexed citations

12.

Guo, Xiang, Ignacio Ferreira González, Nassim Morsli, et al.. (2020). Overall survival modeling and association with serum biomarkers in durvalumab-treated patients with head and neck cancer.. Journal of Clinical Oncology. 38(15_suppl). 6549–6549. 2 indexed citations

13.

Sharma, Padmanee, Joohyuk Sohn, Sang Joon Shin, et al.. (2019). Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. Clinical Cancer Research. 26(1). 61–70. 34 indexed citations

14.

Baverel, Paul, Lorin Roskos, Nancy Lee, et al.. (2019). Exposure–Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status. Clinical and Translational Science. 12(5). 450–458. 16 indexed citations

15.

Baverel, Paul, Dewei She, Edward Piper, et al.. (2017). A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers. Drug Metabolism and Pharmacokinetics. 33(3). 150–158. 15 indexed citations

16.

Baverel, Paul, Yanan Zheng, Xuyang Song, et al.. (2017). Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease Status. Clinical Pharmacology & Therapeutics. 103(4). 631–642. 112 indexed citations

17.

Powles, Thomas, Paul Baverel, Rajesh Narwal, et al.. (2017). Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab.. Journal of Clinical Oncology. 35(15_suppl). 3035–3035. 9 indexed citations

18.

Baverel, Paul, et al.. (2013). Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point. Journal of Allergy and Clinical Immunology. 132(4). 847–855.e5. 66 indexed citations

19.

Baverel, Paul, Radojka M. Savić, & Mats O. Karlsson. (2010). Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models. Journal of Pharmacokinetics and Pharmacodynamics. 38(1). 63–82. 8 indexed citations

20.

Baverel, Paul, Radojka M. Savić, Justin Wilkins, & Mats O. Karlsson. (2009). Evaluation of the nonparametric estimation method in nonmem VI: application to real data. Journal of Pharmacokinetics and Pharmacodynamics. 36(4). 297–315. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact